AstraZeneca (AZN) Rating Reiterated by Deutsche Bank
Deutsche Bank reaffirmed their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Thursday. The firm currently has a GBX 5,700 ($77.30) target price on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on AZN. JPMorgan Chase & Co. set a GBX 5,500 ($74.59) target price on shares of AstraZeneca and gave the stock a buy rating in a research report on Thursday, January 4th. Sanford C. Bernstein set a GBX 5,780 ($78.38) target price on shares of AstraZeneca and gave the stock a buy rating in a research report on Monday, September 25th. Shore Capital restated a hold rating on shares of AstraZeneca in a research report on Tuesday, October 31st. HSBC upped their target price on shares of AstraZeneca from GBX 4,340 ($58.86) to GBX 4,380 ($59.40) and gave the stock a reduce rating in a research report on Thursday, November 16th. Finally, UBS Group set a GBX 4,550 ($61.70) target price on shares of AstraZeneca and gave the stock a neutral rating in a research report on Monday, October 9th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of GBX 5,200.82 ($70.53).
AstraZeneca (LON AZN) opened at GBX 5,132 ($69.60) on Thursday. AstraZeneca has a 1 year low of GBX 4,136.50 ($56.10) and a 1 year high of GBX 5,520 ($74.86). The company has a market cap of $64,070.00 and a PE ratio of 2,515.69.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.